Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2016 07:00 ET | Source: Summit Therapeutics plc

Summit's IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Therapeutics plc("Summit" or "the...
April 26, 2016 07:00 ET | Source: Summit Therapeutics plc

Summit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the US

Enrolment of Patients with DMD in the US Expected to Start 3Q 2016Utrophin Modulation Offers Differentiated Approach in DMD OXFORD, United Kingdom, April 26, 2016 (GLOBE NEWSWIRE) -- Summit...
April 14, 2016 10:10 ET | Source: Summit Therapeutics plc

Summit Therapeutics plc : Exercise of Warrants

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Therapeutics plc("Summit" or "the...
April 11, 2016 07:00 ET | Source: Summit Therapeutics plc

Positive Results from Summit's Phase 2 CoDIFy Trial Presented at 26th ECCMID Conference

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Therapeutics plc ("Summit" or "the...
April 11, 2016 07:00 ET | Source: Summit Therapeutics plc

Positive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile Infection

OXFORD, United Kingdom, April 11, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
April 11, 2016 02:00 ET | Source: Summit Therapeutics plc

Summit Therapeutics plc : Holding(s) in Company

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} TR-1: NOTIFICATION OF MAJOR...
April 06, 2016 07:00 ET | Source: Summit Therapeutics plc

Summit Therapeutics to Present at 15th Annual Needham Healthcare Conference

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Therapeutics plc ("Summit" or the...
March 30, 2016 07:00 ET | Source: Summit Therapeutics plc

Summit Reports Positive Interim Data from Phase 1 Testing a New Formulation of SMT C1100 in DMD Patients

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Therapeutics plc("Summit" or...
March 30, 2016 07:00 ET | Source: Summit Therapeutics plc

Summit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients With DMD

OXFORD, United Kingdom, March 30, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
March 29, 2016 09:25 ET | Source: Summit Therapeutics plc

SUMMIT TO PRESENT ADDITIONAL DATA FROM PHASE 2 CoDIFy TRIAL FOR THE TREATMENT OF C. DIFFICILE INFECTION

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Therapeutics plc ("Summit" or "the...